疑似特发性肺纤维化患者糖皮质激素治疗转归不良
本研究回顾性分析59例接受泼尼松治疗的疑似特发性肺纤维化(posIPF)患者,评估免疫调节治疗转归。
要点
- posIPF患者泼尼松治疗多数无应答,尤其影像有蜂窝影者。
- 治疗前后FVC平均下降从8.7%增至20%(P=0.018)。
核心结论
- 疑似特发性肺纤维化患者接受糖皮质激素治疗可出现加速的FVC下降和大量严重不良事件。
研究设计与样本
- 多中心回顾性队列分析59例接受泼尼松治疗的posIPF患者,起始剂量0.5 mg/kg/day,6个月内逐渐减至0.15 mg/kg/day。
主要发现
- 68%的泼尼松治疗posIPF患者无应答,定义为FVC下降>5%或6个月内死亡。
- 影像学有蜂窝影的患者中90%无应答。
- 7例SLB显示局灶性脱屑性间质性肺炎样反应且戒烟<5年的患者中6例对泼尼松应答,FVC下降<5%。
- 32例有FVC数据的患者治疗前FVC平均下降8.7%(95%CI:3.1-14.3%),治疗后下降20%(95%CI:9.4-31.1%),P=0.018。
临床怎么用
- 对疑似特发性肺纤维化患者,尤其影像有蜂窝影者,应谨慎使用糖皮质激素,因其可能加速肺功能下降并增加严重不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The diagnostic classification of 'possible idiopathic pulmonary fibrosis (posIPF)' is characterized by a radiological pattern of inconsistent usual interstitial pneumonia (UIP) on high-resolution computed tomography (HRCT) scan and a UIP pattern in surgical lung biopsy (SLB). The evidence base to guide treatment for patients with posIPF is lacking; the clinician must choose between observation, treatment with immunomodulatory agents or anti-fibrotic agents. METHODS: To evaluate outcomes of immunomodulatory treatment, a multicentre cohort of 59 posIPF patients treated with prednisone was analysed retrospectively. Prednisone starting dose was 0.5 mg/kg/day and tapered to 0.15 mg/day/kg over 6 months. Outcome measures were forced vital capacity (FVC) and serious adverse events (SAE), defined as death or hospital admissions. RESULTS: The majority of prednisone-treated posIPF patients were non-responders (68%) with a decrease in FVC >5% or death within 6 months from baseline; 90% of patients with radiographical presence of honeycombing were non-responders. In contrast, six out of seven patients with focal desquamative interstitial pneumonia-like reaction in the SLB who had stopped smoking for <5 years ago were responders to prednisone, demonstrating <5% FVC decline. The mean decline of FVC was 8.7% (95% CI: 3.1-14.3%) before treatment and 20% (95% CI: 9.4-31.1%) after treatment (P = 0.018) in the 32 patients with available FVC data. Twelve SAE occurred within the first 3 months on prednisone (at dosage >0.3 mg/kg/day), including five deaths. CONCLUSION: Patients with posIPF demonstrated an accelerated FVC decline and a substantial number of SAE on steroid therapy.
引用
- Wiertz IA, Wuyts WA, van Moorsel CHM, et al. Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. Respirology. 2017. PMID: 29207437. doi:10.1111/resp.13230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。